Home/Filings/4/0000950170-25-079924
4//SEC Filing

Duncan Jason 4

Accession 0000950170-25-079924

CIK 0001885522other

Filed

May 29, 8:00 PM ET

Accepted

May 30, 6:30 PM ET

Size

12.8 KB

Accession

0000950170-25-079924

Insider Transaction Report

Form 4
Period: 2025-05-28
Duncan Jason
See Remarks
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-05-28+400,000400,000 total
    Exercise: $0.72Exp: 2033-12-11Common Stock (400,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-05-28400,0000 total
    Exercise: $1.69Exp: 2033-12-11Common Stock (400,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-05-28500,0000 total
    Exercise: $1.69Exp: 2035-02-13Common Stock (500,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-05-28+500,000500,000 total
    Exercise: $0.72Exp: 2035-02-13Common Stock (500,000 underlying)
Footnotes (4)
  • [F1]25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  • [F2]On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
  • [F3]25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  • [F4]On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Documents

1 file

Issuer

Neumora Therapeutics, Inc.

CIK 0001885522

Entity typeother

Related Parties

1
  • filerCIK 0001741553

Filing Metadata

Form type
4
Filed
May 29, 8:00 PM ET
Accepted
May 30, 6:30 PM ET
Size
12.8 KB